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Nephrology, University of California, San Francisco, San Francisco, CA, United States, 3Department of Pathology, University
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Background: There is an urgent need to develop and implement low cost,
high-throughput standardized methods for routine molecular assessment of transplant
biopsies. Given the vast archive of formalin-fixed and paraffin-embedded (FFPE) tissue
blocks in transplant centers, a reliable protocol for utilizing this tissue bank for clinical
validation of target molecules as predictors of graft outcome over time, would be of
great value.
Methods: We designed and optimized assays to quantify 19 target genes, including
previously reported set of tissue common rejection module (tCRM) genes. We
interrogated their performance for their clinical utility for detection of graft rejection and
inflammation by analyzing gene expression microarrays analysis of 163 renal allograft
biopsies, and subsequently validated in 40 independent FFPE archived kidney transplant
biopsies at a single center.
Results: A QPCR (Fluidigm) and a barcoded oligo-based (NanoString) gene expression
platform were compared for evaluation of amplification of gene expression signal for
19 genes from degraded RNA extracted from FFPE biopsy sections by a set protocol.
Increased expression of the selected 19 genes, that reflect a combination of specific
cellular infiltrates (8/19 genes) and a graft inflammation score (11/19 genes which
computes the tCRM score allowed for segregation of kidney transplant biopsies with
stable allograft function and normal histology from those with histologically confirmed
acute rejection (AR; p = 0.0022, QPCR; p = 0.0036, barcoded assay) and many
cases of histological borderline inflammation (BL). Serial biopsy shaves used for gene
expression were also processed for in-situ hybridization (ISH) for a subset of genes.
ISH confirmed a high degree of correlation of signal amplification and tissue localization.
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Conclusions: Target gene expression amplification across a custom set of genes can
identify AR independent of histology, and quantify inflammation from archival kidney
transplant biopsy tissue, providing a new tool for clinical correlation and outcome analysis
of kidney allografts, without the need for prospective kidney biopsy biobanking efforts.
Keywords: kidney transplantation, acute rejection, biomarker, transcriptomics analysis, FFPE
INTRODUCTION
Renal transplantation is the preferred treatment of end stage
renal disease (ESRD) (1, 2); however, acute rejection, both
T cell mediated rejection (TCMR) or antibody-mediated
rejection (AMR), remain barriers to long-term graft survival.
Current classification methods of histological rejection by
modified Banff classification, suffer from heterogeneities
in biopsy sampling, poor correlations between blinded
pathology reads, and an inability to accurately quantify the
inflammatory burden in the allograft, which is an important
predictor of long-term graft function and survival (3–12).
Unbiased and quantitative measurement of inflammation
in the graft and its evolution over time and with treatment
is an important measure to guide immunosuppression
delivery. Measuring molecular inflammation can also discern
clinical variance in the histological injury of borderline (BL)
characteristics in the kidney, a finding that is not always
detrimental to the allograft, specifically if it is also molecularly
quiescent (13–18).
The tissue common rejection module (tCRM) score is a
computed algorithm to assess inflammatory score for acute
rejection, consisting of 11 genes, originally identified and
validated in over 700 transplant tissue microarrays from
kidney, heart, lung, and liver transplants (5, 19). A tCRM
gene expression score was identified on the microarray
data and then validated by QPCR on RNALater collected
kidney transplant needle biopsies that had been collected
prospectively, as part of biobanking efforts (5). The tCRM
gene expression score of kidney tissues collected at 6 months
directly correlated with risk of progressive interstitial fibrosis
and tubular atrophy on 24 months protocol biopsies (19).
In order to allow this score to be assessed on archival
FFPE tissue blocks, we developed and optimized a protocol
that would allow for target gene analysis on degraded
RNA (11).
In this report, we applied our protocol that measures
gene expression of 19 genes from RNA isolated from four
10-micron shaves off an FFPE block with histologically
confirmed different phenotypes of normal functioning
(NL), T cell-mediated rejection (TCMR), antibody-mediated
rejection (ABMR), borderline changes (BL), and polyoma
virus nephropathy (PVAN). In addition, chromogenic
in situ hybridization (cISH) was employed on assessing
spatial expression of two of the most significant genes
(CXCL9 and CXCL10) on serial sections to demonstrate
biological relevance and accuracy of gene expression data on
FFPE blocks.
METHODS
Patient Enrollment and Study Design
One hundred sixty-three kidney transplant recipient biopsies,
with and without clinical graft dysfunction and matched
biopsy histology, were profiled by oligo-based microarrays and
unsupervised sub-clustering performed across the 19 target
genes. Forty independent renal transplant recipients were
identified with Banff supported diagnosis of acute T cell-
mediated rejection (TCMR, n = 8), antibody-mediated rejection
(ABMR, n = 8), borderline changes (BL, n = 8), polyoma
virus nephropathy (PVAN, n = 8), and normal functioning
(NL, n = 8) were used for clinical validation (Table 1) (20–
23). The basis of inclusion of TCMR, ABMR, BL, and PVAN
was to evaluate heterogeneous injury types. Demographic
information is provided in Table 1. The study was approved
by the Institutional Review Board and Ethics Committee of
the University of California, San Francisco (UCSF), CA. All
patients provided written informed consent to participate in
the research, in full adherence to the Declaration of Helsinki.
The clinical and research activities being reported are consistent
with the Principles of the Declaration of Istanbul as outlined
in the Declaration of Istanbul on Organ Trafficking and
Transplant Tourism.
Histopathology
Tissue cores were fixed in 10% neutral buffered formalin and
embedded in paraffin. First, 2 µm-thick consecutive sections
were cut and stained with hematoxylin and eosin, periodic acid
Schiff (PAS), and PAS-silver as part of the routine diagnostic
workup. Immunofluorescence microscopy was performed
on frozen sections with indirect method for complement
4d (C4d), and direct method for immunoglobulin G (IgG),
IgM, IgA, C3, C1q, fibrinogen and albumin. Classification
into TCMR, ABMR, BL, and NL were based on Banff
classification (20–23). The diagnosis of PVAN required nuclear
positivity in the tubular epithelium by SV-40 stain horseradish
peroxidase-diaminobenzidine tetrahydrochloride detection
method. Estimated glomerular rate (eGFR) was calculated
using Modification of Diet in Renal Disease (MDRD) Study
equation (24).
Interrogation of Microarray Data for the 19
Genes Across Different Kidney Transplant
Injury Phenotypes
Microarray data from 163 kidney transplant biopsies (GSE72925)
was analyzed by unsupervised analysis for sample clustering
across the 19 genes; the 11 CRM genes (BASP, CD6, CXCL10,
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TABLE 1 | Demographic table.
Pathology diagnosis NL (n = 8) BL (n = 8) TCMR (n = 8) ABMR (n = 8) PVAN (n = 8) P-value
Recipient age* (years) 52.9 ± 13.9
(54.0; 37–74)
51.8 ± 11.6
(49.5; 40–74)
48.5 ± 14.9
(46.0; 27–75)
44.6 ± 14.0
(48.5; 17–58)
54.3 ± 13.9
(59.0; 32–69)
0.71 (ns)
Gender (%M) 50.0 50.0 50.0 75.0 75.0 0.65 (ns)
Time post-transplant*
(months)
6.1 ± 0.4
(6.0; 6–7)
6.6 ± 2.8
(6.0; 2–12)
7.6 ± 7.5
(6.0; 0.5–24)
91.6 ± 99.7
(48.0; 0.5–264)
34.3 ± 40.7
(17.5; 4–102)
0.004
eGFR# (ml/min/1.73 m2)* 63.1 ± 12.4
(59.0; 48–87)
51.5 ± 18.4
(49.0; 27–79)
50.3 ± 20.7
(51.0; 21–87)
35.4 ± 23.3
(30.0; 9–69)
35.6 ± 13.1
(36.0; 21–55)
0.02
Creatinine (mg/dL)* 1.2 ± 0.2
(1.1; 0.9–1.5)
1.5 ± 0.5
(1.6; 0.8–2.1)
1.6 ± 0.9
(1.3; 0.6–3.3)
2.8 ± 2.1
(2.0; 1.02–6.62)
2.1 ± 0.6
(2.1; 1.36–3.06)
0.04
Urine protein/Creatinine
(mg Pro/mg Cre)*
0.2 ± 0.0
(0.1; 0.11–0.2)
0.2 ± 0.0
(0.2; 0.11–0.26)
0.2 ± 0.2
(0.1; 0.08–0.53)
3.7 ± 4.6
(2.3; 0.14–14.3)
0.2 ± 0.1
(0.2; 0.08–0.32)
0.006
Transplant type (%) 0.22 (ns)
LRRT 25.0 12.5 12.5 50.0 12.5
LURT 25.0 25.0 12.5 25.0 0.0
DDRT 25.0 62.5 62.5 12.5 75.0
SPK 25.0 0.0 12.5 12.5 0.0
SHK 0.0 0.0 0.0 0.0 12.5
Recipient race (%) 0.80 (ns)
Caucasian 50.0 50.0 25.0 50.0 50.0
Hispanic/Latina 37.5 25.0 12.5 25.0 25.0
Asian 0.0 25.0 25.0 12.5 25.0
African American 12.5 0.0 25.0 0.0 0.0
Hawaiian 0.0 0.0 12.5 0.0 0.0
Other 0.0 0.0 0.0 12.5 0.0
Native renal disease (%) 0.61 (ns)
Hypertension
(HTN)
25.0 12.5 25.0 0.0 0.0
Glomerulonephritis 0.0 12.5 25.0 37.5 12.5
Type I diabetes
(DBI)
25.0 0.0 12.5 12.5 0.0
Type II diabetes
(DBII)
12.5 25.0 12.5 0.0 25.0
HTN + DBI/DBII 12.5 0.0 0.0 0.0 12.5
Unknown 12.5 12.5 0.0 25.0 25.0
Tubulointerstitial
nephritis
12.5 0.0 0.0 0.0 12.5
Polycystic kidney
disease
0.0 37.5 12.5 25.0 12.5
HIV 0.0 0.0 12.5 0.0 0.0
NL, normal graft function; BL, borderline changes; TCMR, T-cell mediated rejection; AMR, antibody mediated rejection; PVAN, polyomavirus; LRRT, living related renal transplant; LURT,
living unrelated renal transplant; DDRT, deceased donor renal transplant; SPK, simultaneous pancreas-kidney transplant; SHK, simultaneous heart-kidney transplant.
*Unit listed: Mean ± SD (Median; Range), P-values for continuous values are calculated with 1 way ANOVA, and for categorical variables with Fisher Exact test.
#eGFR was calculated with Modification of Diet in Renal Disease (MDRD) Study equation (24).
CXCL9, INPP5D, ISG20, LCK, NKG7, PSMB9, RUNX3, TAP1)
and additional eight immune cell specific genes relating
to different cell types, such as overall leukocyte burden
(CD45), B cells (CD20), T cells (CD4, CD8A, FOXP3),
macrophages (CD68), endothelial cells (CD31, PECAM1), and
collagen (COL4A1).
Total RNA Extraction
We followed previously published protocol for the extraction of
RNA from FFPE tissues (11). Based on our previous experience,
we used 4 × 10 µm-thick sections to extract total RNA
from FFPE samples. For rapid purification, PureLink FFPE
Total RNA Isolation Kit was used (Invitrogen, Thermo Fischer
Scientific, Foster City, CA) according to the manufacturer’s
recommendations. The RNA data quality was assessed by
260/280 absorption signal ratio and the RIN number.
NanoString’s Barcoded Oligos Design and
Assay
Barcoded Codesets for each gene studied including 5 reference
genes (GAPDH, GUSB, HPRT1, LDHA, and TBP) used in the
study were designed by NanoString Technologies as a service
(detail information available in Supplemental Table S1). The
NanoString assay was performed (NanoString Technologies,
Seattle, WA) as follows. Briefly, 50 ng of each RNA sample was
added to the CodeSet in hybridization buffer and incubated at
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65◦C for 16 h. The CodeSet consisted of Reporter and Capture
probes that hybridize to the target sequences of interest, forming
a tripartite complex. After the assay, the raw counts for each
assay were collected using the NanoString data analysis software,
nSolver R© (NanoString Technologies, Seattle, WA). Raw counts
were derived from the RCC data files. Normalization of the
data was performed using nSolver R© for the following two
methods. (1) Positive control normalization: gene expression
data is normalized to the mean of the POS control probes for
each assay. (2) RNA content normalization: gene expression data
was normalized to the geometric mean of housekeeping genes in
the CodeSet.
cDNA Synthesis, and Gene Expression
Quantification Using qPCR
A total of 50-ng RNA was reversed transcribed into
complementary DNA (cDNA) using SuperScript VILO
(Invitrogen, Thermo Fischer Scientific, Foster City, CA)
and then amplified in a target specific amplification step for all 19
genes (above) using TaqMan PreAmp Master Mix and TaqMan
Primers and Probes (Invitrogen, Thermo Fischer Scientific,
Foster City, CA) (Supplemental Table S2) for a total of 18
amplification cycles. QPCR reactions were performed in the
Fluidigm BioMark FD system using 18S gene as a housekeeping
gene and Human XpressRef Universal Total RNA (Qiagen,
Valencia, CA) as a reference RNA for 40 cycles. Resulting chip
data was initially analyzed for quality control using the BioMark
Analysis Software Version 2.0 (Fluidigm, South San Francisco,
CA) and Ct values were exported into Excel. Normalization of
the data was done in two steps. (1) Ct values of individual genes
were normalized against Ct value of 18S for each gene to get dCt
values. (2) dCt values of each sample was normalized against
dCt values of the reference sample to get ddCt values which was
subsequently used to calculate fold change (RQ) values for each
gene in each sample.
Statistical Data Analysis and Confounder
Analysis
Because of its steady expression, 18S ribosomal RNA has been
a popular reference RNA in gene expression analyses. For the
QPCR platform, 18S ribosomal RNA was used as the reference
gene. However, for the nCounter system of NanoString, the
system could not handle high abundance of 18S ribosomal
RNA. We chose 5 common reference RNAs (GUSB, HPRT1,
LDHA, TBP, GAPDH) as reference RNAs and used mean
signal as reference value. We tested gene expression correlation
by comparing Ct values of 18S ribosomal RNA with mean
Ct values of the 5 reference RNAs (GUSB, HPRT1, LDHA,
TBP, GAPDH) using 10 FFPE samples. There was a strong
correlation with Pearson correlation (r) of 0.97 (R2 = 0.87)
(P < 0.0001) in between the Ct value of 18S ribosomal RNA
and the mean Ct value of the five reference genes listed above.
This demonstrated that gene expression analyses performed
with either 18S ribosomal RNA or the 5 common reference
genes are comparable. Following reference gene normalization,
QPCR platform data was log2 transformed. Unsupervised and
supervised hierarchical clustering was performed using GENE-
E (https://software.broadinstitute.org/GENE-E/) with utilization
of one minus Pearson correlation and average as the metric and
linkage method, respectively. Correlation values were calculated
using Pearson and Spearman rank-based correlation method
(GraphPad Prism, La Jolla California USA, www.graphpad.com)
where the correlation coefficient, r, ranges from −1 to +1.
Significant difference in two sets of data was determined by
unpaired T-test with two-tailed P-value option and with FDR
correction for multiple testing using two-stage step-up method
of Benjamini, Keieger, and Yekutieli (using GraphPad Prism). A
value of <0.05 was considered significant. The relationship in
between gene expression and the biopsy scores was calculated
using The Jonkheere-Terpstra test. The Spearman rank-order
correlation was performed to calculate rho.
As seen on Table 1, we balanced recipient age, gender,
transplant type, recipient race, and native renal disease (ESRD).
Other parameters, such as serum creatinine, eGFR, and
proteinuria were significantly different among injury phenotypes,
which was expected. Post-transplant times were significantly
different among different injury phenotypes (p = 0.004). A
confounder analysis on gene expression levels of tCRM genes
and months post-transplantation resulted in a p-value of 0.32
demonstrating post-transplantation time was not a factor driving
gene expression values.
Chromogenic ISH (CISH) Assay for CXCL9
and CXCL10
The RNAscope platform (ACD Bio, Newark, CA) was used
to quantify gene transcripts in situ. Probes against two of the
most significant genes in rejection, and with readily available
commercial assays, namely CXCL9 (cat # 440161) and CXCL10
(cat # 311851) (ACD Bio, Newark, CA) were applied on
consecutive 2 µm-thick FFPE tissue sections and were detected
by alkaline-phosphatase-based technique (RNAscope 2.5 HD
Assay—Red) coupled with Warp Red chromogen (Biocare
Medical, Pacheco, CA) followed by hematoxylin counterstain.
Depending on the abundance and distribution of the transcript,
the positive signal can be seen as separate dots or fused
group(s) of multiple dots. After detection, the tissue sections
were digitized by Aperio ScanScope XT. Whole-slide digital
images were analyzed by the Definiens Tissue Studio platform’s
Dot Count module. In brief, the software models an “average”
cell based on the hematoxylin counterstain first, and assigns
each dot to a particular cell and counts them. Thresholds were
adjusted individually and accuracy of the settings was checked by
evaluation of 12 randomly selected HPFs at 40X. The number of
dots in the entire section/1,000 cell characterized the expression
level of a given gene.
RESULTS
Acute Rejection, IFTA, and PVAN Share
Signals of Molecular Inflammation in
Microarray Datasets From 163 Kidney
Transplant Biopsies
Initially, to evaluate the performance of the gene expression of the
selected 19 genes across different transplant injury phenotypes we
evaluated unsupervised interrogation of sample clustering across
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FIGURE 1 | Heterogeneity of kidney graft injury across different injury phenotypes. As anticipated, CRM genes and genes specific to immune related genes are
upregulated in the tissue from recipients of kidney transplantation with AR episodes. In addition, increased gene expression is seen with PVAN and IFTA subtypes.
Furthermore, some tissues from normal graft biopsies also had molecular signatures that correspond to inflammation.
the 19 genes from the microarray data generated on 163 kidney
tissue samples (68 NL, 26 AR, 10 PVAN, and 59 IFTA) (GEO
Accession: GSE72925). As seen in Figure 1, there was an overall
increased expression of most of these genes in AR, supporting
the selection of these markers for rejection detection. The gene
expression in other injury phenotypes including PVAN, IFTA,
and histological and clinically stable biopsies (NL) is seen in
Figure 1, highlighting that molecular inflammation is seen in
biopsies not classified as AR by histology. This observation is
in keeping with other studies that have reported that molecular
inflammation in the graft can be sub-clinical and not always
congruent with histology (25).
Validation of Perturbation of
Transcriptional Signals by Either Fluidigm
or NanoString Methods in FFPE Sections in
Different Transplant Injury Phenotypes
We evaluated gene expression changes in different kidney
transplant phenotypes on 40 independent samples (8 NL, 8
TCMR, 8 ABMR, 8 BL and 8 PVAN) using two platforms
commonly used for quantification of gene expression. Gene
expression data from the NanoString (barcoded oligos) platform
showed significant increases in gene expression level in rejection
(TCMR and ABMR) phenotypes compared to other phenotypes
(including BL, PVAN, and NL) (Figure 2A). Thirteen of the
19 genes tested (BASP1, CXCl10, CXCL9, ISG20, LCK, NKG7,
PSMB9, TAP1, CD31, CD4, CD68, COL4A, PTPRC) showed
significantly increased mRNA levels in injury phenotypes
(TCMR, ABMR, BL, and PVAN) when compared to NL (p
≤ 0.05). More genes were significantly increased in TCMR
(BASP1, CXCL10, CXCL9, INPP5D, ISG20, LCK, RUNX3, CD6,
CD4, COL4A) than in ABMR (INPP5D, ISG20, NKG7, RUNX3,
CD31, CD4, CD68, COL4A) when compared to NL with p-value
≤0.05, highlighting subtle differences in tissue inflammatory
components between TCMR and ABMR.
Similar to the NanoString data, gene expression data from
the QPCR platform showed an overall increased gene expression
level in AR (TCMR and ABMR) phenotypes compared to other
phenotypes (including BL, PVAN, and NL) (Figure 2B). 7 of
the 19 genes assayed (CXCL10, CXCL9, ISG20, LCK, RUNX3,
CD20, CD247) showed an increased mRNA level in injury
phenotypes (TCMR, ABMR, BL, and PVAN) when compared to
NL (p ≤ 0.05). On individual gene level, mRNA transcripts of
CXCL10, LCK, and TAP1 were significantly increased in TCMR
compared to NL (p ≤ 0.05). mRNA transcripts of CD68 and
COL4A were increased in ABMR compared to NL (p ≤ 0.05)
(Supplemental Table S3).
The tCRM Gene Composite Score Is
Specifically Increased in Acute Rejection,
for Both TCMR and ABMR
In the datasets generated by both the platforms used, the CRM
scores for injury phenotypes (TCMR, ABMR, and PVAN) were
significantly higher than the CRM scores for NL phenotypes (p
≤ 0.05). Even though there was a trend of higher CRM scores
for borderline changes (BL), overall these were significantly lower
than those in AR (Figure 3).
We also evaluated association (using Jonkheere-Terpstra test)
with and correlation (using Spearman’s rank-order) of immune
injury related genes’ expression by both the platforms with
biopsy i-score (interstitial inflammation). With NanoString gene
expression data, the expression of CD45 (p = 0.006, rho = 0.41),
CD68 (p = 0.0001, rho = 0.57), CD4 (p = 1.1E-05, rho =
0.62), and CD8A (p = 1.34E-06, rho = 0.68) were all correlated
with i-score significantly. With QPCR gene expression data, the
expression of CD45 (p = 8.53E-05, rho = 0.54), CD68 (p =
3.27E-05, rho = 0.60), CD4 (p = 8.53E-05, rho = 0.54), and
CD8A (p = 0.0003, rho = 0.52) were all correlated with i-score
significantly. Gene expression of COL4A gene was significantly
associated with ct (tubular atrophy) and ci (interstitial fibrosis)
scores with NanoString data (ct, p = 0.05, rho = 0.27, ci, p
Frontiers in Medicine | www.frontiersin.org 5 October 2019 | Volume 6 | Article 213
Sigdel et al. Kidney Tissue Transcription Profiling Assessment
FIGURE 2 | Quantitative methods of gene expression of CRM genes and immune-related genes differentiate kidney transplant biopsies with different transplant
injuries. Expression of the genes across 40 unique samples that included 8 NL, 8 TCMR, 8 ABMR, 8 BL, and 8 PVAN. (A) As quantified by NanoString’s gene
expression platform. (B) As quantified by QPCR (Fluidigm).
= 0.03, rho = 0.30) and QPCR (ct, p = 0.006, rho = 0.39,
ci, p = 0.002, rho = 0.46). This demonstrated the potential
usefulness of the molecular scores in clinical management of the
kidney graft.
Strong Correlation in Between
Chromogenic ISH Signal of CXCL9 and
CXCL10 Gene-Transcripts With Gene
Expression Data
Using RNAscope platform by ACD bio, we quantified gene
transcripts of two genes that are highly expressed in infiltrating
lymphocytes, for CXCL9 and CXCL10, in situ. Depending on the
abundance and distribution of the transcript, the positive signal
can be seen as separate dots or fused group(s) of multiple dots
(as seen in the representative images from biopsy samples with
T-cell mediated rejection). Chromogenic in situ hybridization
for CXCL9 and CXCL10 identified tubular epithelial cells as the
primary source of these chemokines (Figure 4A) while scattered
mononuclear cells also showed some expression (Figure 4B). In
addition, rare signal was noted in some glomeruli; however, no
definite signal was detected in the vascular compartment or in
the interstitium other than the inflammatory cells.
The same FFPE block of a given case was used for both
total RNA isolation and CISH. CISH data for CXCL9 with
spot count/1,000 cells showed a strong correlation with the
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FIGURE 3 | CRM scores are significantly increased in transplant injury. CRM score was used to evaluate difference among different transplant injury phenotypes.
(A) The CRM scores calculated from the NanoString (barcoded oligos) data for injury phenotypes (TCMR, AMR, PVAN) were significantly higher than the CRM scores
for NL phenotypes (p ≤ 0.05). (B) The CRM scores calculated from the QPCR data for injury phenotypes (TCMR, AMR, PVAN) were significantly higher than the CRM
scores for NL phenotypes (p ≤ 0.05). Even though there was a trend of higher CRM scores for borderline changes (BL), they were not significant (p > 0.05) for
both platforms.
FIGURE 4 | Cell specific gene expression of CXCL9 and CXCL10 by
chromogenic in situ hybridization (ciSH) data agrees with gene expression data
on bulk tissue. Representative images from biopsy samples with T-cell
mediated rejection. Chromogenic in situ hybridization for CXCL9 (A) and
CXCL10 (B) shows high-level expression on tubular epithelial cells (asterisks)
and some scattered mononuclear cells (arrow), 400×. Rare signal was noted
in some glomeruli, however no definite signal was detected in the vascular
compartment or in the interstitium other than the inflammatory cells (32, 33).
corresponding gene expression levels on both the NanoString
platform (r = 0.859, p < 0.0005) (Figure 5A) and the Fluidigm
QPCR platform (r = 0.684, p = 0.007) (Figure 5C). CISH
data for CXCL10 with spot count/1,000 cells also showed a
strong correlation with the corresponding gene expression levels
on both the NanoString platform (r = 0.729, p < 0.003)
(Figure 5B) and the QPCR Fluidigm platforms (r = 0.643,
p= 0.018) (Figure 5D).
DISCUSSION
Molecular quantification of the overall inflammatory burden in
the renal allograft is essential to establish at the time of an
invasive biopsy. Our proposed method facilitates data collection
to real-time results (overall experiment times are 4–6 h for the
assays shown) and removes the burden of personnel needed
for onsite prospective biobanking needing immediate tissue
preservation in RNAlater. As a major benefit, we can now process
a valuable clinical set of 19 genes for quantification of tissue
inflammation and AR, using minimal tissue, from archived FFPE
blocks, preserving most of the parent FFPE block for additional
histologic analyses. Understanding the burden of inflammation
in an allograft is critical for optimization of therapy, following
response to chosen interventions and as a means to predict
risk stratification for progressive chronic injury and allograft
loss, when persistent. This study confirms that molecular
profiling provides an objective assessment of graft inflammation,
which can be a very valuable endpoint for observational and
interventional clinical trials (26–28). The recognized difficulty in
capturing and quantifying subtle differences by the histological
scoring system can thus be aided by including a quantitative
molecular scoring system on the same archival biopsy section.
QPCR provides an accurate assessment of gene transcripts in
biological samples, such as blood, biopsy or urine (4, 6, 11, 29–
31). In this study we show that multiplex high-throughput PCR
by Fluidigm or a synthetic oligo based NanoString platform
can further minimize sample input and handle low quality
degraded RNA to amplify a robust set of 19 genes that can be
computed to quantitate the inflammatory burden in the renal
allograft (11). The parallel experiments on serially cut sections
of kidney biopsies demonstrate that there is a strong correlation
of gene expression in situ of prominent infiltrating lymphocyte
markers (CXCL9 and CXCL10) in terms of CISH score with
gene expression data from homogenized tissues. CXCL9 and
CXCL10 were highly expressed in renal tubules during ACR,
and were also found in infiltrating leukocytes in accordance with
the spatial distribution pattern reported previously in a non-
human primate model (32), and human renal transplant biopsies
(33, 34). Strong correlation of gene expression data on serially
sectioned bulk tissue with CISH data provides support of the
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FIGURE 5 | Chromogenic in situ hybridization (ciSH) data correlates with gene expression data on bulk tissue assessed by both Fluidigm and NanoString. We
observed a strong correlation between CXCL9 and CXCL10 cISH spot count and the corresponding gene expression data when applied to a subset of 14 cases [NL
(n = 4), BL (n = 5), and ACR (n = 5)] assessed with NanoString (A,B) and Fluidigm (C,D). The X- and Y-axis values are different in case of NanoString and Fluidigm
because of the different scale of the gene expression values.
biological relevance of the transcriptomic studies on bulk tissues
based on FFPE specimens. This suggests that transcriptomic
profiles preserved in FFPE blocks are both biologically relevant
and clinically beneficial.
We acknowledge that the impact of this study would be
further strengthened by the application of this technology
to a larger number of samples and from its application in
other study groups; the adoption of this assay as a primary
endpoint for ongoing randomized clinical trial (RCT) is expected
to provide additional clinical utility of this assay over time.
Nevertheless, the development of the FFPE section processing
protocol, its reduction to multiplexed PCR, and the validation
of a composite tCRM score as a clinical surrogate endpoint for
rejection and projection of future chronic injury decline, make
strong arguments for this approach to benefit transplant patients
and studies.
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